Claims and disclaimers: whose expertise counts?

Area of Science:

• Medical Anthropology
• Sociology of Science
• Health Policy

Background:

• Interactions between state, clinical, scientific, and lay participants shape illness understandings.
• Competing knowledge claims challenge jurisdictional authority and expertise definitions.
• The Food and Drug Administration (FDA) regulatory processes are central to negotiating knowledge domains.

Purpose of the Study:

• To examine social processes in knowledge domain negotiation and sustenance across authority boundaries.
• To analyze shifting roles of commercial interests, patient groups, and agencies in defining health problems.
• To investigate the redefinition of medical expertise with patient-as-consumer models for pharmaceuticals.

Main Methods:

• Qualitative analysis of regulatory processes at the Food and Drug Administration (FDA).
• Examination of information circulation regarding prescription drugs.
• Case study approach focusing on shifting roles and responsibilities in health problem management.

Main Results:

• New information circulation modes are altering the roles of commercial interests, patient groups, and federal agencies.
• Patient-as-consumer models challenge traditional gatekeepers like physicians and insurance plans.
• The locus of risk, responsibility, credibility, and authority in pharmaceutical decisions is being reconfigured.

Conclusions:

• The definition and practice of medical expertise are evolving due to shifts in pharmaceutical information and decision-making.
• Regulatory processes must adapt to new dynamics of knowledge, authority, and expertise in healthcare.
• Understanding these shifts is crucial for navigating contemporary health landscapes and patient empowerment.